Operational efficiencies of using one vs multiple bispecific antibodies for diffuse large B-cell lymphoma and follicular lymphoma in the US

20260 citationsJournal Article

Authors

Using a single bsAb to treat R/R DLBCL and FL is predicted to lead to considerable time- and cost-savings for oncology practices.

Published in: Future Oncology

Volume 22, Issue 6, pp. 719-727

Field-Weighted Citation Impact: 0.00